
简介:
- 作者: QIROU WU, XIAOHONG LENG, QIAN ZHANG, YE-ZHANG ZHU, RUYUAN ZHOU, YUTONG LIU, CHEN MEI , DAN ZHANG, SHENGDUO LIU, SHASHA CHEN, XIAOJIAN WANG, AIFU LIN, XIA LIN, TINGBO LIANG, LI SHEN, XIN-HUA FENG, BING XIA, AND PINGLONG XU
- 杂志: SCIENCE ADVANCES
- Doi: https://www.doi.org/10.1126/sciadv.adj2102
- 出版日期: 2024 Feb 28
论文中使用的产品/服务
Quotation shows PackGene:HSC- specific deletion of IRF3 was obtained by injection of AAV8 bearing GFAP (promoter)EGFP- Cre into Irf3flox/flox mice through tail vein injection at a dose of 1 × 1011 virus genome (PackGene Biotech), twice in 2 weeks.
Research Field:liver fibrosis
AAV Serotype:AAV8
Targeted organ:liver
Animal or cell line strain:mice
摘要
Cytosolic double-stranded DNA surveillance by cyclic GMP-AMP synthase (cGAS)–Stimulator of Interferon Genes (STING) signaling triggers cellular senescence, autophagy, biased mRNA translation, and interferon-mediated immune responses. However, detailed mechanisms and physiological relevance of STING-induced senescence are not fully understood. Here, we unexpectedly found that interferon regulatory factor 3 (IRF3), activated during innate DNA sensing, forms substantial endogenous complexes in the nucleus with retinoblastoma (RB), a key cell cycle regulator. The IRF3-RB interaction attenuates cyclin-dependent kinase 4/6 (CDK4/6)–mediated RB hyperphosphorylation that mobilizes RB to deactivate E2 family (E2F) transcription factors, thereby driving cells into senescence. STING-IRF3-RB signaling plays a notable role in hepatic stellate cells (HSCs) within various murine models, pushing activated HSCs toward senescence. Accordingly, IRF3 global knockout or conditional deletion in HSCs aggravated liver fibrosis, a process mitigated by the CDK4/6 inhibitor. These findings underscore a straightforward yet vital mechanism of cGAS-STING signaling in inducing cellular senescence and unveil its unexpected biology in limiting liver fibrosis.
关于派真
作为一家专注于AAV 技术十余年,深耕基因治疗领域的CRO&CDMO,派真生物可提供从载体设计、构建到 AAV、慢病毒和 mRNA 服务的一站式解决方案。凭借深厚的技术实力、卓越的运营管理和高标准的服务交付,我们为全球客户提供一站式CMC解决方案,包括从早期概念验证、成药性评估到IIT、IND及BLA的各个阶段。
凭借我们独立知识产权的π-alphaTM 293 细胞AAV高产技术平台,我们能将AAV产量提高多至10倍,每批次产量可达1×10¹⁷vg,以满足多样化的商业化和临床项目需求。此外,我们定制化的mRNA和脂质纳米颗粒(LNP)产品及服务覆盖药物和疫苗开发的各个阶段,从研发到符合GMP的生产,提供端到端的一站式解决方案。
